Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Insulet (PODD) and Gilead Sciences (GILD)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Henry Schein (HSIC), Insulet (PODD) and Gilead Sciences (GILD) with bullish sentiments.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Henry Schein (HSIC)
In a report released today, Allen Lutz from Bank of America Securities maintained a Buy rating on Henry Schein. The company’s shares closed last Thursday at $71.21.
According to TipRanks.com, Lutz is a 5-star analyst with an average return of
Henry Schein has an analyst consensus of Moderate Buy, with a price target consensus of $87.43, implying a 25.2% upside from current levels. In a report issued on May 4, Piper Sandler also maintained a Buy rating on the stock with a $99.00 price target.
See the top stocks recommended by analysts >>
Insulet (PODD)
Bank of America Securities analyst Travis Steed maintained a Buy rating on Insulet today. The company’s shares closed last Thursday at $150.36.
According to TipRanks.com, Steed is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Insulet with a $262.52 average price target, representing a 76.2% upside. In a report issued on May 12, Benchmark Co. also initiated coverage with a Buy rating on the stock with a $250.00 price target.
Gilead Sciences (GILD)
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Gilead Sciences today. The company’s shares closed last Thursday at $132.87.
According to TipRanks.com, Ahmad is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gilead Sciences with a $159.83 average price target, which is a 19.5% upside from current levels. In a report issued on May 5, TipRanks – DeepSeek also upgraded the stock to Buy with a $146.00 price target.
Read More on HSIC:
